Benzinga · Sep 30, 2026
'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
CE
NASDAQ · CERT
Certara, Inc.
Healthcare · Medical - Healthcare Information Services
$10.07
Down-$0.80 (-7.94%)
Updated Oct 7, 2026, 1:38 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.42B
- P/E ratio
- 177.53
- Dividend yield
- 0.00%
- 52-week range
- $4.45 – $10.07
- Volume
- 2.94M
- Avg. volume
- 2.12M
Price performance · CERT
CERT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CERT closed at $10.07 after 20 trading sessions, up 30.10% for the selected period.
- Last close
- $10.07
- Period change
- +30.10%
- Period low
- $7.42
- Period high
- $10.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $9.36 | $10.07 | $9.28 | $10.07 | 2.94M |
| Oct 2, 2026 | $9.41 | $9.45 | $9.045 | $9.36 | 2.65M |
| Oct 1, 2026 | $9.28 | $9.505 | $9.1931 | $9.34 | 3.86M |
| Sep 30, 2026 | $9.16 | $9.345 | $9.135 | $9.20 | 3.42M |
| Sep 29, 2026 | $9.17 | $9.4299 | $9.025 | $9.26 | 2.94M |
| Sep 28, 2026 | $9.00 | $9.34 | $8.92 | $9.13 | 2.94M |
| Sep 25, 2026 | $8.955 | $9.205 | $8.735 | $9.11 | 2.92M |
| Sep 24, 2026 | $8.52 | $8.925 | $8.52 | $8.89 | 2.32M |
| Sep 23, 2026 | $8.82 | $9.125 | $8.59 | $8.64 | 2.59M |
| Sep 22, 2026 | $8.51 | $8.845 | $8.51 | $8.83 | 2.32M |
| Sep 21, 2026 | $8.49 | $8.64 | $8.425 | $8.52 | 1.9M |
| Sep 18, 2026 | $8.58 | $8.65 | $8.165 | $8.42 | 6.72M |
| Sep 17, 2026 | $8.25 | $8.615 | $8.165 | $8.58 | 2.26M |
| Sep 16, 2026 | $8.34 | $8.405 | $8.04 | $8.13 | 3.91M |
| Sep 15, 2026 | $7.97 | $8.40 | $7.949 | $8.40 | 2.12M |
| Sep 14, 2026 | $7.61 | $8.09 | $7.58 | $8.00 | 1.7M |
| Sep 11, 2026 | $7.51 | $7.57 | $7.39 | $7.55 | 1.49M |
| Sep 10, 2026 | $7.52 | $7.61 | $7.31 | $7.42 | 2.26M |
| Sep 9, 2026 | $7.71 | $7.721 | $7.495 | $7.63 | 1.46M |
| Sep 8, 2026 | $7.80 | $7.84 | $7.605 | $7.74 | 2.88M |
Latest CERT news
The latest Smart Investors Daily articles mentioning CERT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CERT research
Overview
Company profile and research snapshot.
Company profile
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Barclays | Equal-Weight | — |
| May 12, 2026 | BMO Capital | Market Perform | — |
| May 12, 2026 | Craig-Hallum | Hold | — |
| May 12, 2026 | Stephens & Co. | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 30, 2026
In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "In-Silico Drug Discovery Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global In-Silico Drug Discovery Market to Reach US$6 Billion by 2030 The global in-silico drug discovery market was valued at US$3.3 billion in 2024 and i
Benzinga · Sep 30, 2026
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
UBS analyst Kevin Caliendo downgrades Certara (NASDAQ:CERT) from Buy to Neutral and maintains the price target from $10 to $10.
Yahoo · Sep 22, 2026
Capitalize on Drug Discovery Informatics: Benchmark Schrödinger, Certara, Dotmatics, Thermo Fisher and BIOVIA to Accelerate R&D ROI and Secure Market Advantage
AI, machine learning and big data are advancing virtual screening and precision medicine, creating opportunities in molecular modeling, docking and data integration.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Informatics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Informatics was estimated at US$4.0 Billion in 2025 and is projected to reach US$8.7 Billion by 2032, growing at a CAGR of 11.9% from 2025
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
